AI Article Synopsis

  • Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a supportive treatment for adults with severe COVID-19-related ARDS, achieving hospital survival rates of 62%-74%, comparable to other conditions requiring ECMO.
  • A study analyzed 46 patients receiving ECMO in Minnesota from March to November 2020, finding that 30 (65.2%) survived for 60 days, with factors such as older age, lower oxygenation levels, and higher organ failure scores linked to higher mortality risk.
  • After initiating ECMO, increased mortality was correlated with longer antibiotic use, more blood transfusions, elevated white blood cell counts, and changes in platelet levels, indicating that infections significantly impact survival outcomes

Article Abstract

Venovenous extracorporeal membrane oxygenation (VV-ECMO) for select adults with severe acute respiratory distress syndrome (ARDS) cause by coronavirus disease 2019 (COVID-19) infection is a guideline-supported therapy with associated hospital survival of 62%-74%, similar to expected survival with VV-ECMO for other indications. However, ECMO is a resource-heavy intervention, and these patients often require long ECMO runs and prolonged intensive care unit (ICU) care. Identifying factors associated with mortality in VV-ECMO patients with COVID-19 infection can inform the evaluation of ECMO candidates as well as prognostication for those patients on prolonged VV-ECMO. This was a retrospective cohort study that included all patients who received either VV- or venoarteriovenous (VAV)-ECMO at one of four ECMO Centers of Excellence in the state of Minnesota between March 1, 2020 and November 1, 2020. The primary outcome was 60-day survival. Secondary outcomes were hospital complications, infectious complications, and complications from ECMO. There were 46 patients who met criteria during this study period and 30 survived to 60-day follow-up (65.2%). Prior to cannulation, older patient age (55.5 in non-survivors vs. 49.1 years in survivors; p = 0.03), lower P/F ratio (62.1 vs. 76.2; p = 0.04), and higher sequential organ failure assessment (SOFA) score (8.1 vs. 6.6; p = 0.02) were identified as risk factors for mortality. After ECMO cannulation, increased mortality was associated with increased number of antibiotic days (25.9 vs. 14.5; p = 0.04), increased number of transfusions (23.9 vs. 9.9; p = 0.03), elevated white blood cell (WBC) count at post-ECMO days one through three, elevated D-dimer at post-ECMO day 21-27, and decreased platelet count from post-ECMO days 14 and onward using univariable analysis. Multiple markers of infection including leukocytosis, thrombocytopenia, and increased antibiotic days are associated with increased mortality in patients placed on VV-ECMO for COVID-19 infection and subsequent ARDS. Knowledge of these factors may assist with determining appropriate candidates for this limited resource as well as direct goals of care in prolonged ECMO courses.

Download full-text PDF

Source
http://dx.doi.org/10.1089/sur.2021.114DOI Listing

Publication Analysis

Top Keywords

covid-19 infection
12
risk factors
8
factors mortality
8
mortality patients
8
venovenous extracorporeal
8
extracorporeal membrane
8
membrane oxygenation
8
acute respiratory
8
respiratory distress
8
distress syndrome
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!